Official answer: There are currently 64 biosimilars approved by the U.S. Food and Drug Administration (FDA). The most recent biosimilar...
An up-to-date resource showing all biosimilars approved in the US as well as biosimilar applications filed with FDA, based on public records. Updated frequently, the number of biosimilars approved for marketing has risen markedly, while the biosimilars l
Biosimilars are the future, each day new products are approved in every single country, giving us new therapeutic alternatives and treating the current and future illnesses the mankind if suffering. We cannot forget that we are all potential patients, and we will want the best quality products to...
Biosimilar infliximab will become available in the UK from early 2015 as the patent for originator infliximab (Remicade) ends. Potentially this is a time of uncertainty for IBD teams and patients as, although biosimilar infliximab is approved for the same indications as the originator product, ...
Biosimilar infliximab will become available in the UK from early 2015 as the patent for originator infliximab (Remicade) ends. Potentially this is a time of uncertainty for IBD teams and patients as, although biosimilar infliximab is approved for the same indications as the originator product, ...
In 2017, a new class of oral disease modifying anti-rheumatic drugs (DMARDs), janus kinase inhibitors (JAKi), were licensed for rheumatoid arthritis (RA): baricitinib and tofacitinib. In the UK, they are approved for use in p... KF Lianne,D Rebecca,W Kath,... - 《Rheumatology》 被引...
Trastuzumab biosimilar is one of the first biosimilars approved in China and has already entered all provincial markets, indicating a broad observational period and a large sample size. Taking trastuzumab as an example, this study analyzed how the consumption of the trastuzumab originator changed ...
Trastuzumab biosimilar is one of the first biosimilars approved in China and has already entered all provincial markets, indicating a broad observational period and a large sample size. Taking trastuzumab as an example, this study analyzed how the consumption of the trastuzumab originator changed ...
1Department of Nephrology,Endocrinology and Metabolic Diseases,Medical University of Silesia,Katowice,Poland and 2Department of Renal Medicine,Morriston Hospital,Swansea,UK Abstract The impending arrival en masse of biosimilars on Western markets is placing drug regulatory agencies under pressure to realign ...
Biosimilars are safe, effective and highly similar versions of approved and authorised biological medicines. They treat the same diseases as the reference biological medicine and with the same efficacy. More >> Biocon Biologics Biocon is giving patients a new lifeline ...